ArticleTranslational oncology2025

LMO2 confers value as a potential immunotherapy marker in pan-cancer analysis and inhibits progression of Clear Cell Renal Cell Carcinoma.

Huiping Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.